20 results on '"Zahar, J.-R."'
Search Results
2. Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review.
- Author
-
Mizrahi A, Delerue T, Morel H, Le Monnier A, Carbonnelle E, Pilmis B, and Zahar JR
- Subjects
- Anti-Bacterial Agents therapeutic use, Colony Count, Microbial, Drug Resistance, Bacterial, Enterobacteriaceae classification, Enterobacteriaceae drug effects, Enterobacteriaceae isolation & purification, Enterobacteriaceae Infections drug therapy, Enterobacteriaceae Infections microbiology, Anti-Bacterial Agents pharmacology, Bacterial Proteins biosynthesis, Cephalosporins pharmacology, Enterobacteriaceae enzymology, beta-Lactamases biosynthesis
- Abstract
The burden of antibiotic-resistant infections among Gram-negative bacteria is increasing. Resistance to third-generation cephalosporins (3GCs) in Enterobacteriaceae is mainly conferred by the acquisition of β-lactamases or by deregulation of natural genetically-encoded β-lactamase enzymes. Enterobacteriaceae such as Enterobacter spp., Serratia marcescens, Citrobacter freundii, Providencia spp. and Morganella morganii (ESCPM group) possess chromosomally-encoded inducible AmpC β-lactamases. AmpC can be overproduced as a response to β-lactam antibiotic exposure or by constitutive dysfunction of the AmpC regulation system. This overproduction can lead to the inactivation of 3GCs. Based on small clinical studies, international guidelines and expert recommendations suggest that 3GCs should be avoided as definitive therapy for infections caused by ESCPM group organisms. In this narrative review, we discuss the published literature and evaluate the risk related to 3GC use in the case of documented ESCPM infection., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
3. Be careful about MICs to amoxicillin for patients with Streptococci-related infective endocarditis.
- Author
-
Pilmis B, Lourtet-Hascoët J, Barraud O, Piau C, Isnard C, Hery-Arnaud G, Amara M, Merens A, Farfour E, Thomas E, Jacquier H, Zahar JR, Bonnet E, and Monnier AL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Endocarditis epidemiology, Endocarditis mortality, Female, France epidemiology, Hospitals, Humans, Male, Microbial Sensitivity Tests methods, Middle Aged, Retrospective Studies, Risk Factors, Streptococcal Infections epidemiology, Streptococcal Infections mortality, Streptococcus classification, Streptococcus isolation & purification, Survival Analysis, Young Adult, Amoxicillin pharmacology, Anti-Bacterial Agents pharmacology, Endocarditis microbiology, Streptococcal Infections microbiology, Streptococcus drug effects
- Abstract
Background: A variety of microorganisms can cause infective endocarditis (IE), with Staphylococci and Streptococci accounting for the majority of cases. Streptococci are a common cause of community-acquired IE but few studies have focused on this subgroup of endocarditis., Methods: A retrospective multicentre study was conducted between 2012 and 2017 in 12 hospital centres in France. Data were extracted from the local diagnosis-related group database and matched with microbiological results. After identification, the records were retrospectively analysed., Results: A total of 414 patients with streptococcal endocarditis were included. The patients were predominantly male (72.8%) and the median age was 73.2 years (interquartile range [IQR] 61.3-80.9). The majority of patients (70.6%) had native valve endocarditis. Embolic complications were seen in 38.8% of patients. Viridans group Streptococci (VGS) and bovis-equinus group Streptococci (BGS) accounted for 52.4% and 34.5% of isolated strains, respectively. Minimum inhibitory concentrations (MICs) of amoxicillin were <0.125, 0.125-2 and >2 mg/L for 59.6%, 27% and 1% of isolates, respectively. In-hospital mortality for patients with Streptococci-related IE was 17.8%. In multivariate analysis, the only factor associated with in-hospital mortality was MIC for amoxicillin between 0.25 and 2 mg/L (P = 0.04; OR = 2.23 [95% confidence interval (CI) 1.03-4.88]) whereas performance of cardiac surgery for IE was a protective factor (P = 0.001, OR = 0.23 [95% CI 0.1-0.56])., Conclusions: IE remains a serious and deadly disease despite recent advances in diagnosis and treatment. Adaptation of antibiotic doses to MICs for amoxicillin and surgery may improve patient outcome., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
4. [Antibiotic prophylaxis in urodynamics: Clinical practice guidelines using a formal consensus method].
- Author
-
Egrot C, Dinh A, Amarenco G, Bernard L, Birgand G, Bruyère F, Chartier-Kastler E, Cosson M, Deffieux X, Denys P, Etienne M, Fatton B, Fritel X, Gamé X, Lawrence C, Lenormand L, Lepelletier D, Lucet JC, Marit Ducamp E, Pulcini C, Robain G, Senneville E, de Sèze M, Sotto A, Zahar JR, Caron F, and Hermieu JF
- Subjects
- Aged, Consensus, Expert Testimony, France, Humans, Urinary Tract Infections diagnosis, Urinary Tract Infections microbiology, Anti-Bacterial Agents therapeutic use, Antibiotic Prophylaxis methods, Antibiotic Prophylaxis standards, Urinary Tract Infections drug therapy, Urodynamics drug effects
- Abstract
Objective: The aim of this work was to issue clinical practice guidelines on antibiotic prophylaxis in urodynamics (urodynamic studies, UDS)., Materials and Methods: Clinical practice guidelines were provided using a formal consensus method. Guidelines proposals were drew up by a multidisciplinary experts group (pilot group = steering group), then rated by a panel of 12 experts (rating group) using a formal consensus method, and then peer reviewed by a reviewing/reading group of experts (different from the rating group)., Results: Urine (bacterial) culture with antimicrobial susceptibility testing is recommended for all patients before UDS (strong agreement). In patients with no neurologic disease, the risk factors for tract urinary infection (UTI) after UDS are age > 70 years, recurrent UTI, and post-void residual volume > 100ml. In patients with neurologic disease, the risk factors for UTI after UDS are recurrent UTI, vesicoureteral reflux, and intermicturition pressure > 40cmH
2 O. If the urine culture is negative before UDS and there is no risk factor for UTI, antibiotic prophylaxis is not recommended (Strong agreement). If the urine culture is negative before UDS, but there are one or more risk factors for UTI, antibiotic prophylaxis is optional. If antibiotic prophylaxis is initiated, a single oral dose (3g) of fosfomycin-tromethamine two hours before UDS is recommended (Strong agreement). If there is bacterial colonization on UCB before UDS, antibiotic therapy is optional (Undecided). If prescribed, it should be adapted to the antimicrobial susceptibility of the identified bacterium or bacteria, started the day before and stopped after UDS (except for fosfomycin-tromethamine: a single dose the day before UDS is necessary and sufficient) (Strong agreement). In the event of UTI before UDS, the UTI should be treated and UDS postponed (Strong agreement). The proposed recommendations should not be changed for patients with a hip or knee replacement (Strong agreement). No antibiotic prophylaxis of bacterial endocarditis is necessary, including in high-risk patients with valvular heart disease (Strong agreement)., Conclusion: These new guidelines should help to harmonize clinical practice and limit exposure to antibiotics., Level of Evidence: 4., (Copyright © 2018. Published by Elsevier Masson SAS.)- Published
- 2018
- Full Text
- View/download PDF
5. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015.
- Author
-
Chervet D, Lortholary O, Zahar JR, Dufougeray A, Pilmis B, and Partouche H
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Anti-Bacterial Agents therapeutic use, Bacterial Proteins analysis, Bacteriuria drug therapy, Bacteriuria microbiology, Community-Acquired Infections drug therapy, Community-Acquired Infections microbiology, Drug Resistance, Bacterial, Escherichia coli drug effects, Escherichia coli enzymology, Escherichia coli isolation & purification, Escherichia coli Infections drug therapy, Escherichia coli Infections epidemiology, Escherichia coli Infections microbiology, Female, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections microbiology, Hospitalization, Humans, Male, Middle Aged, Paris epidemiology, Prospective Studies, Recurrence, Risk Factors, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology, Young Adult, beta-Lactamases analysis, Anti-Bacterial Agents pharmacology, Bacteriuria epidemiology, Community-Acquired Infections epidemiology, Gram-Negative Bacterial Infections epidemiology, Urinary Tract Infections epidemiology
- Abstract
Background: Urinary tract infection (UTI) is one of the most frequent community-acquired infection. Escherichia coli resistance has been on the rise since 2000s., Methods: We conducted a prospective multicenter cohort study including adults who had a positive urine cytobacteriological examination (UCBE) performed in our Parisian suburb laboratory platform from October 2014 to March 2015., Results: A total of 1223 patients were included: 995 (81.4%) women and 228 (18.6%) men. Gram-negative bacilli were isolated in 91% of cases: E. coli accounted for 69.4% of cases. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) prevalence was 4.2%. Resistance of ESBL-producing E. coli strains to amoxicillin, fluoroquinolones, nitrofurantoin, and fosfomycin was respectively 100%, 80%, <5%, and <10%. Risk factors for bacteriuria caused by ESBL-PE were older age (OR=3.7 [1.99-14.4]; P=0.02), recurrent UTI (OR=3.7 [1.9-7.2]; P=0.05), immunosuppression (OR=9.2 [4.1-19.47]; P=0.01), recent hospitalization within the last three months (OR=4.5 [2.3-8.3]; P=0.05), and recent antibiotic therapy (OR=13.4 [6.29-31.9]; P<0.01)., Conclusion: The prevalence of ESBL-PE bacteriuria seems to be 4%. Older age, immunosuppression, recurrent UTI, recent hospitalization, and antibiotic therapy are the main risk factors associated with ESBL-PE community-acquired UTI., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
6. De-escalation of pivotal beta-lactam in ventilator-associated pneumonia does not impact outcome and marginally affects MDR acquisition.
- Author
-
Weiss E, Zahar JR, Garrouste-Orgeas M, Ruckly S, Essaied W, Schwebel C, and Timsit JF
- Subjects
- Carbapenems therapeutic use, Humans, Intensive Care Units, Pneumonia, Ventilator-Associated microbiology, Retrospective Studies, Anti-Bacterial Agents therapeutic use, Drug Resistance, Multiple, Bacterial, Pneumonia, Ventilator-Associated drug therapy, beta-Lactam Resistance, beta-Lactams therapeutic use
- Published
- 2016
- Full Text
- View/download PDF
7. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
- Author
-
Pilmis B, Delory T, Groh M, Weiss E, Emirian A, Lecuyer H, Lesprit P, and Zahar JR
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Cohort Studies, Enterobacter cloacae isolation & purification, Enterobacteriaceae isolation & purification, Enterobacteriaceae Infections microbiology, Escherichia coli isolation & purification, Escherichia coli Infections drug therapy, Female, Humans, Klebsiella pneumoniae isolation & purification, Male, Middle Aged, Prospective Studies, Young Adult, Anti-Bacterial Agents therapeutic use, Carbapenems therapeutic use, Enterobacteriaceae enzymology, Enterobacteriaceae Infections drug therapy, beta-Lactamases analysis
- Abstract
Objectives: To avoid the use of carbapenems, alternatives such as cephamycin, piperacillin-tazobactam, and others are suggested for the treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections. The aim of this study was to evaluate the frequency and the feasibility of antimicrobial de-escalation for ESBL-PE-related infections., Methods: A prospective observational, bi centric cohort study was conducted. All patients with ESBL-PE infections were included. De-escalation was systematically suggested if patients were clinically stable and the isolate was susceptible to possible alternatives., Results: Seventy-nine patients were included: 36 (45.6%) were children, 27 (34.1%) were hospitalized in intensive care units, and 37 (47%) were immunocompromised. Urinary tract infections, pneumonia, and catheter-related bloodstream infections accounted for 45.6%, 19%, and 10%, respectively, of the cohort. Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were the three most frequent causative organisms isolated. On day 5, 47 (59.2%) of the patients were still receiving carbapenems. Antimicrobial resistance (44.7%), infection relapse (26.9%), and clinical instability (19.2%) were the most important reasons for not prescribing alternatives. E. coli-related infections appeared to be a protective factor against maintaining the carbapenem prescription (odds ratio 0.11, 95% confidence interval 0.041-0.324; p=0.0013)., Conclusions: In clinical practice, less than 50% of patients with ESBL-PE-related infections were de-escalated after empirical treatment with carbapenems., (Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
8. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams.
- Author
-
Weiss E, Zahar JR, Lesprit P, Ruppe E, Leone M, Chastre J, Lucet JC, Paugam-Burtz C, Brun-Buisson C, and Timsit JF
- Subjects
- Humans, Selection, Genetic, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Bacterial Infections drug therapy, beta-Lactam Resistance, beta-Lactams administration & dosage, beta-Lactams adverse effects
- Abstract
Empirical broad spectrum antimicrobial therapy prescribed in life-threatening situations should be de-escalated to mitigate the risk of resistance emergence. Definitions of de-escalation (DE) vary among studies, thereby biasing their results. The aim of this study was to provide a consensus definition of DE and to establish a ranking of β-lactam according to both their spectra and their ecological consequences. Twenty-eight experts from intensive care, infectious disease and clinical microbiology were consulted using the Delphi method (four successive questionnaires) from July to November 2013. More than 70% of similar answers to a question were necessary to reach a consensus. According to our consensus definition, DE purpose was to reduce both the spectrum of antimicrobial therapy and the selective pressure on microbiota. DE included switching from combination to monotherapy. A six-rank consensual classification of β-lactams allowing gradation of DE was established. The group was unable to differentiate ecological consequences of molecules included in group 4, i.e. piperacillin/tazobactam, ticarcillin/clavulanic acid, fourth-generation cephalosporin and antipseudomonal third-generation cephalosporin. Furthermore, no consensus was reached on the delay within which DE should be performed and on whether or not the shortening of antibiotic therapy duration should be included in DE definition. This study provides a consensual ranking of β-lactams according to their global ecological consequences that may be helpful in future studies on DE. However, this work also underlines the difficulties of reaching a consensus on the relative ecological impact of each individual drug and on the timing of DE., (Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
9. [Carbapenemase-producing enterobacteriae: epidemiology, strategies to control their spread and issues].
- Author
-
Lepelletier D, Batard E, Berthelot P, Zahar JR, Lucet JC, Fournier S, Jarlier V, and Grandbastien B
- Subjects
- Bacterial Proteins, Enterobacteriaceae Infections drug therapy, Enterobacteriaceae Infections prevention & control, Humans, beta-Lactamases, Anti-Bacterial Agents therapeutic use, Drug Resistance, Multiple, Bacterial drug effects, Enterobacteriaceae drug effects, Enterobacteriaceae Infections epidemiology, Infection Control methods
- Abstract
The increasing bacterial resistance to antibiotics has become a major public health concern bringing the threat of therapeutic impasses. In this context, control of the spread of highly-resistant bacteria emerging antibiotics (BHRe), such as glycopeptide-resistant enterococci (VRE) and Enterobacteriaceae producing carbapenemases (CPE), is based on a dual strategy of reducing the prescription of antibiotics to limit the pressure selection and preventing the spread from carriers. Prevention strategy is based on three different levels such as standard precautions for all patients with a particular focus on the management of excreta, and additional precautions for BHRe carriers. What makes it difficult is that carriage is usually completely asymptomatic, enterobacteria and enterococci are normal commensal of gut microbiota. Explosive dissemination of Enterobacteriaceae producing extended spectrum beta-lactamases in hospital and community heralds the emergence of CPE whose import by patients with a history of hospitalization in abroad may be the main source of spread in France., (Copyright © 2015 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
10. Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use.
- Author
-
Lepeule R, Leflon-Guibout V, Vanjak D, Zahar JR, Lafaurie M, Besson C, and Lefort A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Bacterial Proteins metabolism, Bacteriuria drug therapy, Catheter-Related Infections epidemiology, Catheter-Related Infections microbiology, Child, Child, Preschool, Cross Infection drug therapy, Escherichia coli enzymology, Escherichia coli Infections drug therapy, Escherichia coli Infections epidemiology, Female, Humans, Infant, Infant, Newborn, Male, Microbial Sensitivity Tests, Middle Aged, Paris, Prospective Studies, Risk Factors, Substrate Specificity, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology, Young Adult, beta-Lactam Resistance, beta-Lactamases metabolism, Anti-Bacterial Agents therapeutic use, Escherichia coli isolation & purification, Escherichia coli Infections urine, Inappropriate Prescribing statistics & numerical data, Urine microbiology
- Abstract
Objective: We wanted to describe the clinical features associated with urinalysis positive for ESBL-producing Escherichia coli and their impact on antibiotic use., Methods: We performed a prospective observational study in 13 French hospitals of the Paris area for 3 consecutive months. We included all patients with urine cultures positive for ESBL-producing E. coli., Results: One hundred and seventeen of the 218 patients (54%) presented with asymptomatic bacteriuria, 31 (14%) with cystitis, and 70 (32%) with a parenchymal infection. Nineteen patients with asymptomatic bacteriuria (16%) received antibiotics. Forty-one with parenchymal infections (59%) received a carbapenem. A carbapenem alternative could have been used in every patient treated with a carbapenem, according to antibiotic susceptibility testing results., Conclusions: Urinary tract infections accounted for 46% of E. coli ESBL positive urinalysis. Fifty percent of parenchymal infections were treated with a carbapenem., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
11. Antibiotic dosing in the critically ill: asking the same questions but expecting different answers.
- Author
-
Póvoa P, Spriet I, and Zahar JR
- Subjects
- Female, Humans, Male, Anti-Bacterial Agents administration & dosage, Bacterial Infections drug therapy, beta-Lactams administration & dosage
- Published
- 2014
- Full Text
- View/download PDF
12. Management of multidrug resistant bacterial endemic.
- Author
-
Zahar JR and Lesprit P
- Subjects
- Enterobacteriaceae isolation & purification, Enterobacteriaceae Infections epidemiology, France epidemiology, Hand Hygiene, Humans, beta-Lactamases, Anti-Bacterial Agents therapeutic use, Drug Resistance, Multiple, Bacterial, Endemic Diseases prevention & control, Enterobacteriaceae drug effects, Enterobacteriaceae Infections drug therapy
- Abstract
The fight against multi-drug resistant Gram-negative bacilli (MDRGNB), especially extended-spectrum β-lactamase producing Enterobacteriaceae, is about to be lost in our country. The emergence of new resistance mechanisms to carbapenems in these Enterobacteriaceae exposes patients to a risk of treatment failure without any other therapeutic options. This dramatic situation is paradoxical because we are well aware of the 2 major factors responsible for this situation: 1) MDRO cross-transmission, associated with a low compliance to standard precautions, especially hand hygiene, and 2) overexposure of patients to antibiotics. The implementation of a "search and isolate" policy, which was justified to control the spread of some MDRO that remained rare in the country, was not associated with a better adherence to standard precautions. The antibiotic policy and the measures implemented to control antibiotic consumptions have rarely been enforced and have shown inconsistent results. Notably, no significant decrease of antibiotic consumption has been observed. There is no excuse for these poor results, because some authors evaluating the effectiveness of programs for the control of MDRO have reported their positive effects on antimicrobial resistance without any detrimental effects. It is now urgent to deal with the 2 major factors by establishing an educational and persuasive program with quantified and opposable objectives. Firstly, we have to improve the observance of hand hygiene above 70%. Secondly, we have to define and reach a target for the reduction of antibiotic consumption both in community and in hospital settings., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
13. Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli.
- Author
-
Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, Bille E, Jullien V, and Zahar JR
- Subjects
- Anti-Bacterial Agents pharmacokinetics, Carbapenems pharmacokinetics, Carbapenems pharmacology, Cefoxitin pharmacokinetics, Drug Administration Schedule, Drug Dosage Calculations, Escherichia coli enzymology, Escherichia coli genetics, Escherichia coli growth & development, Escherichia coli Infections drug therapy, Escherichia coli Infections microbiology, Gene Expression, Humans, Microbial Sensitivity Tests, Pyelonephritis drug therapy, Pyelonephritis microbiology, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology, beta-Lactamases biosynthesis, beta-Lactamases genetics, Anti-Bacterial Agents pharmacology, Cefoxitin pharmacology, Escherichia coli drug effects, Models, Statistical, beta-Lactam Resistance
- Abstract
Cefoxitin could be an alternative to carbapenems in extended-spectrum-beta-lactamase-producing Escherichia coli (ESBL-EC) infections. However, pharmacological and clinical data regarding cefoxitin are limited. Using a recent pharmacological model and the MICs of ESBL-EC collected from pyelonephritis, we determined the probabilities to reach four pharmacological targets: free cefoxitin concentrations above the MIC during 50% and 100% of the administration interval (T>MIC = 50% and T>MIC = 100%, respectively) and free cefoxitin concentrations above 4× MIC during 50% and 100% of the administration interval (T>4MIC = 50% and T>4MIC = 100%, respectively). Cefoxitin could be used to treat ESBL-EC pyelonephritis, but administration modalities should be optimized according to MICs in order to reach pharmacological targets., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF
14. Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae.
- Author
-
Pilmis B, Parize P, Zahar JR, and Lortholary O
- Subjects
- Adult, Anti-Bacterial Agents pharmacology, Bacterial Proteins biosynthesis, Carbapenems pharmacology, Cephamycins pharmacology, Child, Child, Preschool, Enterobacteriaceae Infections microbiology, Female, Humans, Male, Retrospective Studies, Sepsis microbiology, Urinary Tract Infections microbiology, beta-Lactam Resistance, beta-Lactamases biosynthesis, Anti-Bacterial Agents therapeutic use, Carbapenems therapeutic use, Cephamycins therapeutic use, Enterobacteriaceae enzymology, Enterobacteriaceae Infections drug therapy, Sepsis drug therapy, Urinary Tract Infections drug therapy
- Published
- 2014
- Full Text
- View/download PDF
15. Gram-negative bacteremia: which empirical antibiotic therapy?
- Author
-
Shoai Tehrani M, Hajage D, Fihman V, Tankovic J, Cau S, Day N, Visseaux C, Carbonnelle E, Kouatchet A, Cattoir V, Nhan TX, Corvec S, Jacquier H, Jauréguy F, Le Monnier A, Morand P, and Zahar JR
- Subjects
- Aged, Cephalosporin Resistance, Community-Acquired Infections drug therapy, Humans, Prospective Studies, Anti-Bacterial Agents therapeutic use, Bacteremia drug therapy, Gram-Negative Bacterial Infections drug therapy
- Abstract
Purpose: Given the increasing frequency of cefotaxime-resistant strains, third-generation cephalosporins (3GC e.g. cefotaxime, ceftriaxone) might not be recommended any longer as empirical antibiotic therapy for community-acquired Gram-negative bacteremia (CA-GNB)., Patients and Methods: We conducted a multicenter prospective descriptive study including patients with CA-GNB., Results: Two hundred and nineteen patients were included. Escherichia coli and Pseudomonas aeruginosa were the most frequently isolated species in 63% (n=138) and 11% (n=24) of the cases, respectively. The prevalence of cefotaxime-resistance reached 18% (n=39) mostly due to intrinsic resistance (27 cases, 12%). The presence of invasive material (P<0.001), the origin of the patient (Paris region or West of France) (P=0.006), and home health care (P<0.001) were variables predicting resistant GNB. The negative predictive value for resistance in patients with invasive material coming from the West of France, or without invasive material and with home health care was 94%. The positive predictive value for patients with invasive material living in Paris, or without invasive material and with home health care only reached 58 and 54%, respectively., Conclusions: Using 3GC for CA-GNB due to cefotaxime-resistant strains was relatively frequent, ESBL-producing Enterobacteriaceae being rarely involved. Our study highlights the role of local epidemiology; before any changes to first-line antibiotic therapy, local epidemiological data should be taken into account., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
16. [Antibiotic treatment of appendicular peritonitis in children: is the oral route done?].
- Author
-
Berthe-Aucejo A, Postaire M, Cheikhlard A, Zahar JR, and Bourget P
- Subjects
- Administration, Oral, Adolescent, Child, Child, Preschool, Cohort Studies, Female, France, Humans, Infusions, Intravenous, Length of Stay, Male, Practice Guidelines as Topic, Retrospective Studies, Anti-Bacterial Agents administration & dosage, Appendicitis drug therapy, Peritonitis drug therapy
- Abstract
The use of intravenously administered antibiotics has several disadvantages including hospitalization costs, infectious risk, and patient discomfort. The objective of this study was to estimate the proportion of children receiving intravenous antibiotic therapy (IV), for whom there was a switch to an oral route conforming to the criteria established by the American Pediatric Surgical Association (APSA). A cohort of 100 children hospitalized for acute appendicitis with generalized peritonitis or abscess were analyzed. In this study, we compared the criteria of switching to an oral route as recommended by the APSA (disappearance of the pain, normalization of white blood cells, afebrile for 48 hours, return to bowel function) and by reports from the literature (afebrile, tolerating regular diet). In 47.5% of the children, there was a switch to an oral route conforming to the APSA recommendations. In children having a late switch, the average duration of the IV treatment was of 7.6 ± 3.6 days associated with 62 days of avoidable IV antibiotics. The duration of hospitalization and antibiotic treatment was significantly higher in children having a late switch (P=0.04; P=0.01, respectively). Concerning the criteria reported in the literature, 14.5% of children were not switched to an oral route. Meeting the criteria from the literature would have resulted in 199 days of avoidable IV antibiotics. A significant number of days of IV antibiotics could have been avoided. However, the large number of exclusion criteria in the APSA analysis suggests that practitioners do not follow these recommendations or objective criteria. The criteria proposed in the literature could decrease the duration of IV antibiotics and the associated hospitalization costs., (Copyright © 2012 Elsevier Masson SAS. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
17. [Optimized clinical use of vancomycin, a prospective observational study in a Paris teaching hospital].
- Author
-
Taieb F, Le Monnier A, Bille E, Lanternier F, Mechai F, Ribadeau-Dumas F, Maenulein E, Forge C, Corriol O, Nassif X, Lortholary O, and Zahar JR
- Subjects
- Adult, Hospitals, Teaching, Humans, Paris, Prospective Studies, Anti-Bacterial Agents administration & dosage, Vancomycin administration & dosage
- Abstract
Introduction: Vancomycin is still the cornerstone of antibiotic therapy for patients with suspected or proven invasive methicillin resistant Staphylococcus aureus infections. However, clinical and pharmacodynamic studies underline that appropriate doses depend on the infection site, the patient's weight, his renal function, and the bacterial susceptibility., Objective and Method: In this prospective study made in a Paris teaching hospital, our two goals were to describe the modalities of infusion and serum concentration obtained during therapy, in our pediatrics and adults population., Results: In our hospital, vancomycin was administered every eight hours in 83 % (97/102) of the cases and the doses used were 30 mg/kg per day in 67 % of cases (68/102). Serum trough levels reached 15 mcg/ml and 20 mcg/ml in 36 % and 18 % of cases respectively. Moreover, despite adequate doses, trough levels of 15 mcg/ml were obtained in only 40 % of cases., Conclusion: Vancomycin infusion use could be optimized, by defining optimal serum concentrations and monitoring made by a mobile team of infectious diseases specialists., (Copyright 2009 Elsevier Masson SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
18. [Two cases of Bacillus infection and immunodepression].
- Author
-
Farhat H, Chachaty E, Antoun S, Nitenberg G, and Zahar JR
- Subjects
- Amoxicillin therapeutic use, Ceftriaxone therapeutic use, Ciprofloxacin therapeutic use, Clavulanic Acid therapeutic use, Drug Therapy, Combination, Humans, Immunosuppression Therapy, Male, Middle Aged, Shock, Septic etiology, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Bacillus isolation & purification, Bacterial Infections immunology, Sepsis immunology, Shock, Septic immunology
- Abstract
Objective: Members of the genus Bacillus are Gram-positive bacilli, ubiquitous in the environment. When isolated in clinical practice, it is frequently considered as due to environmental contamination. Bacillus cereus is the most frequent species isolated in clinical practice, nevertheless other Bacillus spp. are sometimes isolated. Bacillus bacteremia is uncommon, the affected patients are severely ill and frequently immunocompromised with hematological malignancies., Study Design: Two cases of bloodstream infection due to Bacillus species rarely described before are described, one due to Bacillus macerans and the other to Bacillus pumilus. Both patients presented with severe bacteremia and were immunodepressed after recent chemotherapy. They died a few days after admission to our ICU., Conclusion: The initial report of Bacillus spp. isolated in blood culture in oncohematological patients indicates a potentially severe infection.
- Published
- 2008
- Full Text
- View/download PDF
19. Is it time to reconsider initial antibiotic treatment strategies for severe urinary tract infections in Europe?
- Author
-
Zahar JR, Lecuit M, Carbonnelle E, Ribadeau-Dumas F, Nassif X, and Lortholary O
- Subjects
- Drug Resistance, Bacterial, Enterobacteriaceae drug effects, Enterobacteriaceae enzymology, Europe, Humans, Urinary Tract Infections microbiology, beta-Lactamases biosynthesis, Anti-Bacterial Agents therapeutic use, Urinary Tract Infections drug therapy
- Abstract
Until recently, most reported cases of bacteraemia caused by multidrug-resistant strains of Enterobacteriacae producing an extended-spectrum beta-lactamase (ESBL) in Europe have been nosocomial in origin. However, increasing numbers of reports of community-acquired bacteraemia and urinary tract infection caused by ESBL-producing microorganisms suggest that the geographical origin of patients should be taken into account as a risk-factor for possible ESBL production. Early identification of patients at high-risk of infection with ESBL-producing microorganisms, based on their geographical origin and travel history, should help to optimise initial antibiotic treatment strategies for severe urinary tract infections in Europe.
- Published
- 2007
- Full Text
- View/download PDF
20. Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints
- Author
-
Farfour, E., Degand, N., Riverain, E., Fihman, V., Le Brun, C., Péan de Ponfilly, G., Muggeo, A., Jousset, A., Piau, C., Lesprit, P., Chatelain, N., Dortet, L., Poisson, A., Guillard, T., Limelette, A., Mizrahi, A., Le Monnier, A., Fournier, D., Potron, A., Morand, P., Janvier, F., Otto, M.-P., Woerther, P.-L., Decousser, J.-W., Corvec, S., Plouzeau-Jayle, C., Broutin, L., Yin, N., Héry-Arnaud, G., Beauruelle, C., Grillon, Antoine, Lecuru, M., Bille, E., Godreuil, S., Jean Pierre, H., Jean-Pierre, Hélène, Amara, M., Henry, A., Zahar, J.-R., Carbonelle, E., Jaureguy, F., Lomont, A., Isnard, C., Cattoir, V., Canis, F., Diedrich, T., Flevin, E., Merens, A., Jacquier, H., Gyde, E., Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Besançon (CHU Besançon), Hôpital Foch [Suresnes], Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Henri Mondor, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Universitaire de Reims (CHU Reims), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CHU Pontchaillou [Rennes], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hopital d'instruction des armées Sainte-Anne [Toulon] (HIA), CHU Henri Mondor, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Virulence bactérienne précoce : fonctions cellulaires et contrôle de l'infection aiguë et subaiguë, Université de Strasbourg (UNISTRA), CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Hydrosciences Montpellier (HSM), Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier de Versailles André Mignot (CHV), Hôpital Avicenne [AP-HP], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire [Rennes], Centre hospitalier [Valenciennes, Nord], Centre hospitalier de Dieppe, Hôpital d'Instruction des Armées Begin, and Service de Santé des Armées
- Subjects
Klebsiella spp ,[SDV]Life Sciences [q-bio] ,Microbial Sensitivity Tests ,Fosfomycin ,Biology ,Microbiology ,03 medical and health sciences ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Enterobacterales ,Drug Resistance, Bacterial ,medicine ,ComputingMilieux_MISCELLANEOUS ,0303 health sciences ,Bacteria ,030306 microbiology ,Breakpoint ,Broth microdilution ,Anti-Bacterial Agents ,3. Good health ,Infectious Diseases ,T Urinary tract infection ,Practice Guidelines as Topic ,EUCAS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,medicine.drug - Abstract
The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24mm versus 19mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, P0.01) and reached 2.8% and 86.5% in E. coli and K. pneumoniae, respectively. French guidelines for the management of community-acquired UTI remain appropriate. The accuracy of the methods for routine fosfomycin susceptibility testing should be assessed. The role of fosfomycin in the treatment of documented CA-UTI due to Enterobacterales other than E. coli should be evaluated considering its rate of resistance and recent data reporting low accuracy.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.